ALLO

Allogene Therapeutics, Inc.

BS score 50.8MEDIUMPHASE2 · mkt cap $709.4M · rev ttm $0

drug hypothesis

cemacabtagene ansegedleucel (cema-cel, previously ALLO-501A) modulates CD19 to treat First-line consolidation for newly diagnosed Large B-Cell Lymphoma (LBCL) patients who achieve complete or partial response to initial chemoimmunotherapy but remain minimal residual disease (MRD) positive.

moa:Allogeneic CAR T cell therapy engineered with TALEN® gene-editing to lack functional T cell receptors (preventing GvHD), designed to target and kill CD19-expressing B cells in patients with Large B-Cell Lymphoma.

score breakdown

trial design35

base rate disconnect42

language red flags100

composite50.8

valuation analysis

market cap$709.4M

revenue ttm$0

phasePHASE2

historical base rate10%

disconnect ratio1.4x

lead trialNCT06500273

meta

cik0001737287

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

ALPHA3 is a Phase 2 pivotal registrational trialrandomizing approximately 220-250 patients who achieve complete response or partial response to first-line chemoimmunotherapy but are MRD positive (using Foresight Diagnostics assay). Patients randomized to receive cema-cel consolidation with FC lymphodepletion (fludarabine/cyclophosphamide) or standard observation. Following a Grade 5 treatment-related SAE in the FCA arm (with ALLO-647), that arm was discontinued in August 2025 and ALLO-647 development terminated. Trial includes interim futility analysis once 12 patients per arm enrolled and followed for MRD conversion.

primary endpoint:Event-free survival (EFS) per independent review committee assessment

claimed differentiation

Off-the-shelf allogeneic CAR T enables treatment to be delivered faster, more reliably, at greater scale, and to more patients compared to autologous CAR T; positioned as potentially the only CAR T in first-line (1L) consolidation setting in community cancer centers where most newly diagnosed patients receive care

language red flags

'Potentially groundbreaking' and 'may leapfrog other CAR T's' - speculative marketing language without supporting data
'Transform autoimmune management' - overpromising for early-stage program
Heavy reliance on executive team's prior success at Kite (Yescarta) as validation of current approach
Multiple forward-looking statements with 'we believe', 'we anticipate', 'could' - extensive hedging
'First-line consolidation' approach represents significant deviation from approved CAR T indications but safety concerns (Grade 5 SAE) already emerged
Proprietary Dagger® technology and 'next-generation' claims without specific comparative efficacy data
'Potentially curative' language used repeatedly for therapies in early development
RMAT designation obtained but still exploring partnering opportunities for ALLO-316, suggesting internal prioritization concerns
ALLO-647 discontinued due to safety but was integral to original trial design - raises questions about platform robustness

company-stated risks

Risk of graft-versus-host disease (GvHD) where allogeneic T cells recognize patient's normal tissue as foreign
Risk of premature rejection of infused allogeneic CAR T cells by host immune system
Manufacturing challenges inherent to complex cell therapy production
Competition from other CAR T therapies and alternative treatment modalities
Regulatory risks including potential for additional safety signals to impact approval pathway
Uncertainty around scalability and commercial manufacturing capabilities
Risk that MRD assay may not accurately identify patients who would benefit from consolidation

upcoming catalysts

April 2026MRD clearance data from interim futility analysis
June 2026Initial proof-of-concept data for ALLO-329 in autoimmune disease
End of 2027Complete enrollment in ALPHA3 trial